triple anti-tuberculosis drug

PreclinicalSmall molecule

FFirst Affiliated Hospital of Harbin Medical University

triple anti-tuberculosis drug is one of 7 small molecule programs targeting Granuloma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GranulomaActive, not recruiting

GranulomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Granuloma

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Rayos

RRoxane Laboratories

Approved

1 3

Olumiant

Eli Lilly

Phase 2

1 4

Doxycyclin

TTanta University

Preclinical

1 5

Corticosteroid Therapy

Sanofi

Preclinical

1 6

Sclerotherapy

UUniversity of Minnesota

Preclinical

1 7

triple anti-tuberculosis drug

FFirst Affiliated Hospital of Harbin Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Granuloma1 trial

Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis

Recruiting·FFirst Affiliated Hospital of Harbin Medical University··NCT06565845·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for triple anti-tuberculosis drug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — triple anti-tuberculosis drug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for triple anti-tuberculosis drug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Harbin Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFirst Affiliated Hospital of Harbin Medical University

triple anti-tuberculosis drug

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Granuloma1 trial

References

Drug Info

Quick Facts

Related News